The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Open accessAbstract
Enhancers, critical determinants of cellular identity, are commonly recognized by correlative chromatin marks and gain-of-function potential, although only loss-of-function studies can demonstrate their requirement in the native genomic context. Previously, we identified an erythroid enhancer of human BCL11A, subject to common genetic variation associated with the fetal haemoglobin level, the mouse orthologue of which is necessary for erythroid BCL11A expression. Here we develop pooled clustered regularly interspaced palindromic repeat (CRISPR)-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their architecture diverges. The crucial human sequences appear to be primate-specific. Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for fetal haemoglobin reinduction. The detailed enhancer map will inform therapeutic genome editing, and the screening approach described here is generally applicable to functional interrogation of non-coding genomic elements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The authors flow-sorted the edited cells on the basis of the BCL11A-dependent switch to fetal haemoglobin, sequenced guides enriched in cells that had or hadn’t switched, and on the basis of those enrichments, successfully identified a primate-specific GATA1 motif critical for that enhancer’s function.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Cas9 introduces a targeted double-strand break, which is repaired by homology-directed repair using the donor templates, resulting in the incorporation of a single variant at the endogenous genomic locus (54, 55).”
From Massively parallel functional genomic assays in endocrinology: from promise to delivery (2026) · cites this paper as [54]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first such screen targeted gRNAs to effectively tile small indels across a known cluster of enhancers of BCL11A195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Canver et al 9 recently showed BCL11A enhancer disruption by CRISPR/Cas9 could induce fetal haemoglobin in both mice and primary human erythroblast cells.”
From What is CRISPR/Cas9? (2016) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The initial CRISPR screens of regulatory elements delivered an individual gRNA per cell195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
The cited source says what the claim attributes to it.
In the citing paper
“To date, all such screens use Cas9-induced perturbations, including active Cas9 for sequence disruption195, or nuclease dead-Cas9 (dCas9) tethered to an epigenetic repressor105 or activator domain92.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
In the citing paper
“In contrast, nine recently published CRISPR screens of noncoding sequences cumulatively studied regulatory effects on a total of 17 genes (Canver et al., 2015; Diao et al., 2016, 2017; Fulco et al., 2016; Gasperini et al., 2017; Klann et al., 2017; Korkmaz et al., 2016; Rajagopal et al., 2016; Sanjana et al., 2016).”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
In the citing paper
“First, they focus on the regulation of a single gene per experiment, typically entailing the development of a gene-specific assay.”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationRNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Self-citationGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHistone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
FIMO: scanning for occurrences of a given motif
Grant, C. E., Bailey, T. L., & Noble, W. S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr064 · Cited by 4,247
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Systematic Localization of Common Disease-Associated Variation in Regulatory DNA
Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., Reynolds, A. P., Sandstrom, R., Qu, H., Brody, J., et al. (2012) · Science · doi:10.1126/science.1222794 · Cited by 3,716
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
Self-citation
Cited by
Sorted by citations
Items 701–800 of 883
Machine learning tools for deciphering the regulatory logic of enhancers in health and disease
Foutadakis, S., Bourika, V., Styliara, I., Koufargyris, P., Safarika, A., & Karakike, E. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1603687 · Cited by 2
Benyahia, B., Brumano, L. P., Pessoa, A., & da Silva, F. V. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-444-64301-8.00002-0 · Cited by 2
Medicine: Expanding possibilities
Gewin, V. L. (2015) · Nature · doi:10.1038/528s10a · Cited by 2
Cleavage-free human genome editing
Kuang, C., Xiao, Y., & Hondmann, D. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.12.001 · Cited by 2
Treatment of sickle cell disease: Beyond hydroxyurea
Mishra, P. P. (2022) · Journal of Hematology and Allied Sciences · doi:10.25259/jhas_6_2022 · Cited by 3
The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment
Lai, M. I., & Ahmed, N. H. M. (2022) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x23666230123140926 · Cited by 3
Suwito, B. E., Adji, A. S., Widjaja, J. S., Angel, S. C. S., Hajiri, A. Z. Z. A., Salamy, N. F. W., & Choirotussanijjah, C. (2023) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2023.11435 · Cited by 3
Gene editing technology for improving life quality: A dream coming true?
Ramezankhani, R., Minaei, N., Haddadi, M., Torabi, S., Hesaraki, M., Mirzaei, H., Vosough, M., & Verfaillie, C. M. (2020) · Clinical Genetics · doi:10.1111/cge.13794 · Cited by 2
Reversible inhibition of specific transcription factor-DNA interactions using CRISPRPreprint
Shariati, A., Dominguez, A. A., Wernig, M., Qi, L. S., & Skotheim, J. M. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/282681 · Cited by 2
Molecular scissors cut in on stem cells
Azvolinsky, A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0467-6 · Cited by 2
ZNF410 represses fetal globin by devoted control of CHD4/NuRDPreprint
Vinjamur, D. S., Yao, Q., Cole, M. A., McGuckin, C., Ren, C., Zeng, J., Hossain, M., Luk, K., Wolfe, S. A., Pinello, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.31.272856 · Cited by 2
Self-citationDiscovery and Functional Characterization of Pro-growth Enhancers in Human Cancer CellsPreprint
Chen, P.-S. B., Fiaux, P. C., Li, B., Zhang, K., Kubo, N., Jiang, S., Hu, R., Wu, S.-H., Wang, M.-C., Wang, W., et al. (2021) · bioRxiv · doi:10.1101/2021.02.04.429675 · Cited by 3
Glaser, L. V., Steiger, M., Fuchs, A., van Bömmel, A., Einfeldt, E., Chung, H. R., Vingron, M., & Meijsing, S. H. (2021) · MDC Repository (Max-Delbrueck-Center for Molecular Medicine) · Cited by 2
The value of political connections : evidence from Korean chaebols
Choi, M. (2014) · Cited by 2
Brusson, M., Chalumeau, A., Martinucci, P., Romano, O., Poletti, V., Scaramuzza, S., Ramadier, S., Masson, C., Ferrari, G., Mavilio, F., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.31.522279 · Cited by 2
All wired up: heptads in hematopoiesis
Ng, A. P. (2023) · Blood · doi:10.1182/blood.2023022014 · Cited by 2
Functional Annotation of the Major Histocompatibility Complex LocusPreprint
Bounds, L. R., Barrera, A., ter Weele, M. A., Liu, S., Wu, E. Y., Li, S., Venukuttan, R., Rai, R., Mu, W., Iglesias, N., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.01.703124 · Cited by 3
Detection of gene cis-regulatory element perturbations in single-cell transcriptomes
Yeo, G. H. T., Juez, O., Chen, Q., Banerjee, B., Chu, L., Shen, M. W., Sabry, M., Logister, I., Sherwood, R. I., & Gifford, D. K. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008789 · Cited by 1
The role of enhancers in psoriasis and atopic dermatitis
Sui, J. Y., Eichenfield, D. Z., & Sun, B. K. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad321 · Cited by 2
Genetic modifications of EGLN1 reactivate HbF production in β0-thalassemia/HbE
Jan‐ngam, V., Boontha, S., Tubsuwan, A., Wongpalee, S. P., Fanhchaksai, K., Tantiworawit, A., Charoenkwan, P., & Khamphikham, P. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38020 · Cited by 1
Une approche CRISPR/Cas pour traiter les β-hémoglobinopathies
Brusson, M., & Miccio, A. (2025) · médecine/sciences · doi:10.1051/medsci/2024191 · Cited by 2
Biphasic control of the B cell transcriptome by mTORC1 and GSK3
Kalchschmidt, J., Kanno, T., Park, S., du Bois, W., Zhao, Y., Trzaskoma, P., Thomas, C. J., Staudt, L. M., O’Shea, J. J., Jung, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116361 · Cited by 1
The histone methyltransferase MLL1 complex inhibits expression of fetal hemoglobin
Han, Y., Gudmundsdottir, B., Gudmundsson, K. O., Roy, K. R., Tisdale, J. F., & Du, Y. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110863 · Cited by 1
Butt, H., Sathish, S., London, E., Le, A., Li, Q., Gudmundsdottir, B., Lee, D., Burke, E. V., Yates, B. P., Liu, D. R., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017321 · Cited by 3
A new advance in therapeutic induction of fetal hemoglobin on an uncertain road to durable access
Manwani, D. G., Capellera-Garcia, S., & Weiss, M. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.030 · Cited by 1
Emerging Considerations in Transfusion Medicine
Gibson, N. M., Kwiatkowski, J. L., & Chou, S. T. (2025) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2025.10.006 · Cited by 1
Complex HBB gene editing outcomes revealed by a fluorescent reporter cell model
Karsenty, C. L., Betancourth, D., Cao, M., Pham, Q.-K., Park, S. H., & Bao, G. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102854 · Cited by 1
Shu, H., Luan, A., Wang, Y., He, J., Wei, Q., Zhan, R., & Chang, S. (2026) · Frontiers in Plant Science · doi:10.3389/fpls.2026.1769495 · Cited by 1
Nucleotide-resolution mapping of regulatory elements via allelic readout of tiled base editing
Becerra, B., Wittibschlager, S., Patel, Z. M., Kutschat, A. P., Delano, J., Che, E., Tauber, A., Wu, T., Starrs, M. M., Horstmann, C. S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69918-8 · Cited by 1
Self-citationCRISPR in Thalassemia: Global Research Trend Analysis
Saboor, M., Alblooshi, M. J., Alkaabi, A. A., Soozaei, F. R., & Alketbi, M. H. (2026) · Hemoglobin · doi:10.1080/03630269.2026.2634815 · Cited by 1
New Gene Therapy Strategy for β-Thalassemia
Liang, D., Schmidt‐Wolf, I. G. H., & Pu, J. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11132-6 · Cited by 1
CRISPR: Taking the Shortcut to a Healthy Genome Editing Enterprise
Papadaki, M. (2016) · Regenerative Medicine · doi:10.2217/rme-2016-0012 · Cited by 1
From the Beauty of Genomic Landscapes to the Strength of Transcriptional Mechanisms
Natoli, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.011 · Cited by 1
Molecular Chipper: Functional Mapping of the Non-Coding Genome with CRISPR
Cheng, J., Pan, W. Q., & Roden, C. (2016) · Journal of Next Generation Sequencing & Applications · doi:10.4172/2469-9853.1000132 · Cited by 1
A chance to cut (the genome) is a chance to cure
Montbleau, K. E., & Sankaran, V. G. (2018) · Blood · doi:10.1182/blood-2018-03-839787 · Cited by 1
CRISPR: A Promising Tool for Cancer Therapy
Mohammad‐Rafiei, F., Safdarian, E., Adel, B., Vandchali, N. R., Navashenaq, J. G., & Hayat, S. M. G. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220624111311 · Cited by 1
Tumor-promoting function and regulatory landscape of PD-L2 in B-cell lymphoma
Shingaki, S., Koya, J., Yuasa, M., Saito, Y., Tabata, M., McClure, M. B., Ogawa, S., Katayama, K., Togashi, Y., Imoto, S., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01772-1 · Cited by 1
Hacking hematopoiesis – emerging tools for examining variant effects
Gundry, M. C., & Sankaran, V. G. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.049857 · Cited by 1
Using Synthetic DNA Libraries to Investigate Chromatin and Gene Regulation
Kleinschmidt, H., Xu, C., & Bai, L. (2023) · Chromosoma · doi:10.1007/s00412-023-00796-5 · Cited by 2
Mechanistic and Biological Perspectives on Erythropoiesis
Bresnick, E. H., Papayannopoulou, T., & Migliaccio, A. R. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104286 · Cited by 1
Gene Therapy: The Path Toward Becoming a Realistic Cure for Sickle Cell Disease
Leonard, A. K., & Abraham, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62328-3_15 · Cited by 1
Interrogating the noncoding genome in a high-throughput fashion
Zhou, Z. L., & Wei, W. (2018) · National Science Review · doi:10.1093/nsr/nwy138 · Cited by 1
Gentherapie von Hämoglobinkrankheiten – aktuelle Konzepte und Herausforderungen
Kulozik, A. E., & Kunz, J. B. (2019) · Transfusionsmedizin · doi:10.1055/a-0825-9666 · Cited by 2
Role of CRISPR-Cas/9 in Hematological Disorders: A Review
Sharma, S. (2021) · Archives in Biomedical Engineering & Biotechnology · doi:10.33552/abeb.2021.05.000613 · Cited by 1
Interrogation of Enhancer Function by Enhanced CRISPR Epigenetic EditingPreprint
Li, K., Liu, Y., Cao, H., Zhang, Y., Gu, Z., Liu, X., Yu, A., Kaphle, P., Dickerson, K. E., Ni, M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/761247 · Cited by 1
Development of a CRISPR-based epigenetic screening method
Köferle, A. (2017) · UCL Discovery (University College London) · Cited by 1
Alda-Catalinas, C., Ibarra-Soria, X., Flouri, C., Gordillo, J. E., Cousminer, D. L., Hutchinson, A., Krejčí, A., Cortés, A., Acevedo, A., Malla, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.14.540711 · Cited by 1
Benchmarking Perturbation Tools for the Noncoding GenomePreprint
Zhang, H., Luo, S., Wang, X., Lin, L., Liang, R., Zhong, C., Zhang, Y., Zhao, W., Chen, Z., Liu, X., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.21.683665 · Cited by 1
AI platform for CRISPR functional mapping and function-based drug designPreprint
Ngo, J. C., Schoonenberg, V. A. C., Nandakumar, R., Wu, X., & Sher, F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.06.722817 · Cited by 1
Self-citationMaretty, L., Sibbesen, J. A., & Krogh, A. (2014)
Genome editing and stem cell therapy pave the path for new treatment of sickle-cell disease.
Randolph, M. K., & Zhao, W. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2306-9759.2015.11.02
Barriers to Effective Genome Editing of Haematopoietic Stem Cells
Howe, S. J., & Milsom, M. D. (2016) · Current Stem Cell Reports · doi:10.1007/s40778-016-0032-x
Gene Therapy for Haemoglobinopathies
Goodman, M., & Malik, P. (2016) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0025347
Personalized Medicine and Blood Disorders
Zhang, L. (2016) · Personalized Medicine · doi:10.2217/pme-2016-0043
Dzik, S., & Murphy, M. F. (2017) · doi:10.1002/9781119129431.ch1
Promoter or enhancer activation by CRISPRa rescues haploinsufficiency caused obesityPreprint
Matharu, N. K., Rattanasopha, S., Maliskova, L., Wang, Y., Hardin, A. I., Vaisse, C., & Ahituv, N. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/140426
Raghavan, A. (2017) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Dense sgRNA Library Construction Using a Molecular Chipper Approach
Cheng, J., Pan, W. Q., & Lü, J. (2017) · BIO-PROTOCOL · doi:10.21769/bioprotoc.2373
CRISPRing the Regulatory Genome, the Challenge Ahead
Sansbury, S. E., Sweeney, K. M., & Shalem, O. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.07.001
Self-citationGenomeditierung in der Zell- und Gentherapie
Pruszak, J., Müller, M., König, S., & Cathomen, T. (2017) · Transfusionsmedizin · doi:10.1055/s-0043-105031
Elucidation of Mechanisms of Fetal Hemoglobin Regulation by CRISPR/Cas9 Mediated Genome Editing
Canver, M. C. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Self-citationGenome Editing During Development Using the CRISPR-Cas Technology
Arzate‐Mejía, R. G., Licona-Limón, P., & Targa, F. R. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7714-7_16
Unite to Cure: CRISPR Comes to the Vatican
Davies, K. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.29017.vat
Cheung, R., Insigne, K. D., Yao, D., Burghard, C. P., Jones, E. M., Goodman, D. B., & Kosuri, S. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3188378
Kuzmich, A. I., Zinovyeva, M. V., Potapov, V. K., Костина, М. Б., & Sverdlov, E. D. (2018) · Molecular Genetics Microbiology and Virology · doi:10.3103/s0891416818010081
Genome Editing Technologies: From Bench Side to Bedside
Tuncay, F. Y., & Dinçer, P. (2018) · Acta Medica · doi:10.32552/2018.actamedica.282
Investigation of transcription factor binding at distal regulatory elements
Mitchelmore, J. (2017) · Apollo (University of Cambridge) · doi:10.17863/cam.25144
Mannstadt, M., & Wein, M. N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804182-6.00006-x
Impactos das Tecnologias nas Ciências Biológicas e da Saúde 3
Slivinski, C. T. (2019) · doi:10.22533/at.ed.377191601
Howaidi, J., Howaidi, A., & Howaidi, F. (2019) · Journal of Nature and Science of Medicine · doi:10.4103/jnsm.jnsm_52_18
Patel, B. B., Lebensohn, A. M., Pusapati, G. V., Carette, J. E., Salzman, J., & Rohatgi, R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0198463
Discovering functional sequences with RELICS, an analysis method for tiling CRISPR screensPreprint
Fiaux, P. C., Chen, H. V., Chen, A. R., Chen, P. B., & McVicker, G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/687293
Integrative Modeling and Novel Technologies in Human Genomics
Carmona-Mora, P., & Young, J. I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816573-7.00008-0
Misc. medical devices and technologies
Basu, P., Vadlapatla, R., Kumar, P., & Gray, J. P. (2019) · Side effects of drugs annual · doi:10.1016/bs.seda.2019.08.008
Enhancing CRISPR deletion via pharmacological delay of DNA-PKPreprint
Bosch, N., Medová, M., Esposito, R., Pulido-Quetglas, C., Zimmer, Y., & Johnson, R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.12.945907
CRISPR Screening Explores New Dimensions
Eisenstein, M. S. (2020) · Genetic Engineering & Biotechnology News · doi:10.1089/gen.40.07.07
Parallel genetics of regulatory sequences in vivoPreprint
Froehlich, J. J., Uyar, B., Herzog, M., Theil, K., Glažar, P., Akalin, A., & Rajewsky, N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.28.224998
Application of genome editing technology in human gene therapy
Mitani, K. (2020) · Translational and Regulatory Sciences · doi:10.33611/trs.2020-007 · Cited by 1
CRISPR-Decryptr reveals cis-regulatory elements from noncoding perturbation screensPreprint
Rasmussen, A. W., Äijö, T., Gabitto, M. I., Carriero, N. J., Sanjana, N. E., Skok, J. A., & Bonneau, R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.13.247007
Self-citationMayers, J. G. (2019) · TSpace (University of Toronto)
Vaiani, E., Chen, Y.-S., Ramírez, P., Racca, J. D., Baquedano, M., Malosetti, C., Touzon, M., Marino, R., Costanzo, M., Bailez, M., et al. (2021) · bioRxiv · doi:10.1101/2021.05.05.442859
Mohammed, Z. S., & Al-Kraity, W. R. H. (2021) · Medico-Legal Update · doi:10.37506/mlu.v21i2.2878
Sher, F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817876-8.00004-8
Self-citation“Priority delivery” options for gene therapy
Loke, J. C. T. (2021) · Blood · doi:10.1182/blood.2021012761
Suh, Y. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737623696.793579913
Gene Therapy: Hemoglobinopathies
(2015) · Sage eBooks · doi:10.4135/9781483347660.n159
Guigó, R. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726903777.793554170
Sharrocks, A. D. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735667505.793560965
Natarajan, R. D. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734622402.793555449
Yip, K. Y.-L. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734622402.793557563
Saitsu, H. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737001613.793572920
Mefford, H. C. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736437709.793571951
Sharrocks, A. D. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738702238.793579142
Kuzmich, A. I., Zinovyeva, M. V., Potapov, V. K., Костина, М. Б., & Sverdlov, E. D. (2018) · Molecular Genetics Microbiology and Virology (Russian) · doi:10.18821/0208-0613-2018-36-1-3-8
CRISPR base editing of cis -regulatory elements enables target gene perturbationsPreprint
Lim, C. K. W., McCallister, T. X., Saporito-Magriñá, C., McPheron, G. D., Krishnan, R., C., M. A. Z., Powell, J. E., Clark, L. V., Pérez‐Piñera, P., & Gaj, T. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.26.493649
Yang, F., Pang, J., Liu, G., Yang, Y., Qin, S., Zhang, Y., Lai, Y., Liang, D., & Wu, Y. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.05.506576
D’Gama, J. D., Park, J. S., & Waldor, M. K. (2022) · Wiley eBooks · doi:10.1002/9781683673798.ch13
Genome Editing with CRISPR‐Cas Systems
Lotfy, P., & Hsu, P. D. (2022) · Wiley eBooks · doi:10.1002/9781683673798.ch11
Metadata
- Authors
- Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., Luc, S., Kurita, R., Nakamura, Y., Fujiwara, Y., Maeda, T., Yuan, G.-C., Zhang, F., Orkin, S. H., & Bauer, D. E.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Broad Institute (US)
- RIKEN BioResource Research Center (JP)
- University of Tsukuba (JP)
- Brigham and Women's Hospital (US)
- Corresponding author
- Zhang, Feng
- Orkin, Stuart H.
- Bauer, Daniel E.
- ORCID
- Venue
- Nature
- Published
- 2015-09-16
- Volume
- 527
- Issue
- 7577
- Pages
- 192-197
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4644101
- OpenAlex
- W1855348513
- Cited by
- 886
- References
- 65
- Citations by year
- 2026: 43 · 2025: 72 · 2024: 76 · 2023: 79 · 2022: 68 · 2021: 91 · 2020: 85 · 2019: 92 · 2018: 87 · 2017: 94 · 2016: 89 · 2015: 8
- FWCI
- 51.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion)
- PMC
- Funders
- Howard Hughes Medical Institute
- U.S. Public Health Service (R01 A1084905)
- National Heart, Lung, and Blood Institute (P01HL032262, R01HL032259, R01HL119099)
- National Institute of Mental Health (DP1MH100706, R01MH110049)
- National Human Genome Research Institute (K99HG008171, R01HG005085, K99HG008399)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK049216, 5R01-DK097768, R01DK097768, F30DK103359, K08DK093705)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- BCL11A, enhancers, CRISPR/Cas9, fetal hemoglobin, sickle cell disease, beta-thalassemia, enhancer architecture, erythroblasts
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Animals, Base Sequence, Carrier Proteins, Cells, Cultured, DNA-Binding Proteins, Enhancer Elements, Genetic, Erythroblasts, Fetal Hemoglobin, Genetic Engineering, Humans, Molecular Sequence Data, Nuclear Proteins, Organ Specificity, Repressor Proteins, Species Specificity, Reproducibility of Results, Mutagenesis, Genome, Mice, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
